

IANN#1758341, VOL 0, ISS 0

# Local ocular renin–angiotensin–aldosterone system: any connection with intraocular pressure? A comprehensive review

Mervi Holappa, Heikki Vapaatalo, and Anu Vaajanen

## QUERY SHEET

This page lists questions we have about your paper. The numbers displayed at left are hyperlinked to the location of the query in your paper.

The title and author names are listed on this sheet as they will be published, both on your paper and on the Table of Contents. Please review and ensure the information is correct and advise us if any changes need to be made. In addition, please review your paper as a whole for typographical and essential corrections.

Your PDF proof has been enabled so that you can comment on the proof directly using Adobe Acrobat. For further information on marking corrections using Acrobat, please visit <http://journalauthors.tandf.co.uk/production/acrobat.asp>; <https://authorservices.taylorandfrancis.com/how-to-correct-proofs-with-adobe/>

The CrossRef database ([www.crossref.org/](http://www.crossref.org/)) has been used to validate the references.

## AUTHOR QUERIES

- Q1** Please provide the volume number for Reference [15].
- Q2** References [46 and 104], [160 and 185], [223 and 226] are duplicate references so we have removed one and retained other. Kindly confirm.
- Q3** Please note that the references have been renumbered to make their text citations sequential. Please check.
- Q4** Please note that Figure 1 will be set in black and white in print. Please rephrase the legends so that there is no reference to any colours.

REVIEW ARTICLE



# Local ocular renin–angiotensin–aldosterone system: any connection with intraocular pressure? A comprehensive review

Mervi Holappa<sup>a</sup>, Heikki Vapaatalo<sup>a</sup> and Anu Vaajanen<sup>b</sup>

<sup>a</sup>Medical Faculty, Department of Pharmacology, University of Helsinki, Helsinki, Finland; <sup>b</sup>Department of Ophthalmology, Tampere University Hospital, Tampere, Finland

## ABSTRACT

The renin–angiotensin system (RAS) is one of the oldest and most extensively studied human peptide cascades, well-known for its role in regulating blood pressure. When aldosterone is included, RAAS is involved also in fluid and electrolyte homeostasis. There are two main axes of RAAS: (1) Angiotensin (1–7), angiotensin converting enzyme 2 and Mas receptor (ACE2–Ang(1–7)–MasR), (2) Angiotensin II, angiotensin converting enzyme 1 and angiotensin II type 1 receptor (ACE1–AngII–AT1R). In its entirety, RAAS comprises dozens of angiotensin peptides, peptidases and seven receptors. The first mentioned axis is known to counterbalance the deleterious effects of the latter axis. In addition to the systemic RAAS, tissue-specific regulatory systems have been described in various organs, evidence that RAAS is both an endocrine and an autocrine system. These local regulatory systems, such as the one present in the vascular endothelium, are responsible for long-term regional changes. A local RAAS and its components have been detected in many structures of the human eye. This review focuses on the local ocular RAAS in the anterior part of the eye, its possible role in aqueous humour dynamics and intraocular pressure as well as RAAS as a potential target for anti-glaucomatous drugs.

## KEY MESSAGES

- Components of renin–angiotensin–aldosterone system have been detected in different structures of the human eye, introducing the concept of a local intraocular renin–angiotensin–aldosterone system (RAAS).
- Evidence is accumulating that the local ocular RAAS is involved in aqueous humour dynamics, regulation of intraocular pressure, neuroprotection and ocular pathology making components of RAAS attractive candidates when developing new effective ways to treat glaucoma.

**Abbreviations:** ACE1: angiotensin-converting enzyme 1; ACE2: angiotensin-converting enzyme related carboxypeptidase, angiotensin converting enzyme 2; AGT: angiotensinogen; AH: aqueous humour; AMD: age-related macular degeneration; Ang (X-X): angiotensin (following numbers in parenthesis refer to the numbers of amino acid residues); Ang I, II, III, IV: angiotensin I, II, III, IV; Ang A: angiotensin A; AP-A, -N, -M, -B: aminopeptidase-A, -N, -M, -B; ARB: Ang II type 1 receptor blocker; AT1R, -2R, -4R: angiotensin II type 1, -2, -4 receptor; B1/B2 receptor: bradykinin receptor; BMP: bone morphogenetic protein; BP: blood pressure; CAGE: chymostatin-sensitive Ang II generating enzyme; CP: carboxypeptidase; CTGF: connective tissue growth factor; DIZE: diminazene aceturate; DP: diabetic retinopathy; ECM: extracellular matrix; EM: electron microscope; EP: endopeptidase; fXIIa: factor XII activated; HPLC: high performance liquid chromatography; HSD1 and 2: 11 $\beta$ -hydroxysteroid dehydrogenase type 1 and 2; ICC: immunocytochemistry; ICH: immunohistochemistry; IF: indirect immunofluorescence; IOP: intraocular pressure; ISH: *in situ* hybridization; MasR: Mas receptor, Ang (1–7) receptor type; MgrD: Mas-related G-protein-coupled receptor D; MR: mineralocorticoid receptor; MS: mass spectrometry; NEP: neprilysin; NO: nitric oxide; NPE: non-pigmented ciliary epithelium; NTG: normal tension glaucoma; PAI-1: plasminogen activator inhibitor 1; PCP: prolyl-carboxypeptidase; PEP: prolyl-endopeptidase; (P)RR: (pro)renin receptor; RAAS: renin–angiotensin–aldosterone system; RIA: radioimmunoassay; ROP: retinopathy of prematurity; TGF- $\beta$ : transforming growth factor  $\beta$ ; tPA: tissue-type plasminogen activator

## ARTICLE HISTORY

Received 20 January 2020  
Accepted 15 April 2020

## KEYWORDS

ACE1; ACE2; angiotensin II; angiotensin (1–7); angiotensin receptors; Mas receptor; aldosterone; mineralocorticoid receptor; glaucoma; intraocular pressure

## Introduction

Glaucoma is one of the leading causes of blindness, globally affecting approximately 80 million people in 2020 [1,2]. Due to the fact that glaucoma can be asymptomatic for a long time, the number of people suffering from glaucoma is probably much higher. It is estimated that 20 years from now, there will be over 100 million people suffering from glaucoma [2].

Glaucoma, with its numerous subtypes, is a multifactorial neurodegenerative disease in which damage to the optic nerve and retinal ganglion cell axons cause visual field defects and irreversible vision loss [3–5]. If left untreated, glaucoma can lead to total blindness. Even though the underlying mechanism in glaucoma aetiology is still incompletely understood, different genetic and biological risk factors, such as age, race, family history, diabetes as well as structural properties like pseudoexfoliation and myopia have been identified [6–8]. Intraocular pressure (IOP) is considered to be the most important of all the risk factors so far identified for glaucoma [4,9]. The complex aetiology of glaucoma complicates the development of effective therapies [3,10]. Thus today, only treatments capable of lowering the IOP have been proven effective in slowing down disease progression [11,12]. Recently, it has been proposed that more attention should be paid to neuroprotective agents and therapies for glaucoma treatment [13,14].

Interestingly, a local ocular RAAS in the human eye has been associated with the development of glaucoma and other eye disorders such as diabetic retinopathy (DR), age-related macular degeneration (AMD) and retinopathy of prematurity (ROP) [15–21]. In this review, we focus on a local ocular RAAS and its possible connection to aqueous humour (AH) dynamics and hence to the pathology of glaucoma as well as the potential role of this local RAAS in neuroprotection. A literature search was conducted with PubMed and Google Scholar using the following search terms and their combinations to narrow down the literature: AH, IOP, RAS, tissue RAS, aldosterone, angiotensin, Ang I, Ang II, Ang (1–7), Ang (1–9), Ang (3–4), alamanidine, ACE1 and ACE2, MasR, Mas-related G-protein coupled receptor D (MrgD), angiotensin receptor, AT1R, AT2R, AT4R, eye disorder, glaucoma and neuroprotection. Eventually 239 articles were chosen based on their relevance.

## Renin–angiotensin–aldosterone system


The origins of RAAS research can be traced back to 1898 when the Finnish scientist Robert Tigerstedt and

his Swedish student Per Bergman were examining a kidney extract and identified a blood pressure (BP) elevating substance, later called renin [22–24]. Now today, over 120 years after its initial discovery, our understanding of the RAAS cascade and its components has expanded and it now has a recognized role in (patho)physiology [23]. Indeed, several enzymes, peptides and receptors operating within RAAS cascade have been identified during the last century e.g. new targets on which to focus in drug development [25–28]. Today, much of the RAAS research concentrates on the two main axes of RAAS as well as how disturbances in the interaction of these two axes can lead to pathological events not only at the systemic but also at the level of individual organs [28]. Figure 1 illustrates the complexity of the RAAS cascade. This review will focus mainly on the key components of RAAS, which means that several peptidases, proteases and peptides lie beyond the scope. In addition, the Kallikrein–Kinin system, which is recognized to interact at multiple levels with RAAS, is not examined in detail here [16].

## Systemic RAAS

Renin is a highly specific aspartyl protease; it activates the RAAS cascade by hydrolysing its only known substrate: angiotensinogen (AGT) to angiotensin I (Ang I) [29]. AGT is the precursor of all of the angiotensin peptides; AGT is mainly synthesized and released into the bloodstream from the liver, e.g. in response to inflammation, insulin and oestrogen [30]. Interestingly, some organs, such as heart and kidney, are also known to produce AGT [30]. Renin, on the other hand, is mainly synthesized, stored and released in renal juxtaglomerular cells in response to decreased arterial BP, reductions in sodium levels or increased activity of sympathetic nervous system [31,32]. Renin is synthesized as an inactive form called prorenin [33]. The prosequence is first cleaved by kallikrein, cathepsin B or proconvertase before fully active renin is released into the circulation [31,33]. Renin, and its less active form prorenin, can mediate vasoconstrictive effects *via* (pro)renin receptor ((P)RR) [33–35].

When formed, a weak prohormone and vasoconstrictor Ang I, which is a decapeptide, is usually further cleaved into smaller peptides such as the octapeptide, angiotensin II (Ang II) by angiotensin converting enzyme type 1 (ACE1) [36] or other enzymes such as tonin [37], trypsin [38], kallikrein [39], cathepsin G [40] and chymase [41–43]. The last five enzymes listed above are regarded as alternative pathways for the



**Q4 Figure 1.** The renin–angiotensin–aldosterone system. The two main axes of the RAAS cascade: ACE1–Ang II–AT1R axis (blue lines), ACE2–Ang (1–7)–MasR axis (red lines) are highlighted in colour. As many of the angiotensin peptides can interact with several distinctive receptors, reduced affinity is illustrated with dashed lines. One novel route, ACE2–alamandine–MgrD (green lines) could constitute a new protective axis of RAAS as alamandine and its receptor MrgD have similar functions to Ang (1–7) and MasR i.e. exerting vasodilating and antiproliferative effects. The effect of Ang II and Ang III to stimulate aldosterone release is shown with grey lines. In order that aldosterone can bind to its receptor, MR, the HSD2 enzyme must be present in order to convert cortisol to cortisone as cortisol binds to MR with much higher affinity than aldosterone. In the kallikrein–kinin system, kallikreins release vasoactive peptides, i.e. kinins, from their substrates, kininogens. The crosstalk between RAAS and the kallikrein–kinin system occurs at the peptide, enzyme as well as the receptor levels. ACE1: Angiotensin-converting enzyme 1; ACE2: Angiotensin-converting enzyme related carboxypeptidase; Ang I, II, III, IV: Angiotensin I, II, III, IV; Ang A: Angiotensin A; AT1R, –2R, –4R: Angiotensin II type 1, –2, –4 receptor; AP: Aminopeptidase (-A, -N, -M, -B); B1/B2 receptor: Bradykinin receptors; CAGE: Chymostatin-sensitive Ang II generating enzyme; CP: Carboxypeptidase; EP: Endopeptidase; fXIIa: factor XII activated; HSD2: 11 $\beta$ -hydroxysteroid dehydrogenase type 2; MgrD: Mas-related G-protein-coupled receptor D; MasR: Mas receptor, Ang(1–7) receptor type; MR: mineralocorticoid receptor; NEP: Neprilysin; PCP: Prolyl-carboxypeptidase; PEP: Prolyl-endopeptidase; tPA: Tissue-type plasminogen activator. In angiotensin peptides, the numbers in parenthesis refers to the numbers of amino acid residues. The figure is updated from Vaajanen et al. [210].

production of Ang II which may be important in (patho)physiology [44–46] but will not be discussed further in this review. ACE1 is present locally in various tissues and body fluids [47]. In order to convert Ang I into Ang II, i.e. the removal of two amino acid residues from the carboxyl terminus of Ang I, ACE1 needs chloride to improve substrate binding as well as the presence of Zn<sup>2+</sup> which is complexed with activated water molecule in the enzyme's active site [36,48]. Since the ACE1 mediating pathway is considered to be the main pathway for the formation of Ang II, blockade of ACE1 reduces Ang II concentrations and on the other hand, elevates Ang (1–7) levels [49]. This

explains why ACE inhibitors are widely used as antihypertensive medications [50]. However, the enzymes involved in the alternative pathways for Ang II formation may attempt to restore the decline in Ang II levels evoked by ACE1 inhibition [49].

Ang II is a vasoactive peptide that exerts its physiological effect such as vasoconstriction, fibrosis and inflammation *via* G-protein coupled angiotensin type 1 receptor (AT1R) [51–53]. Ang II also stimulates the release of aldosterone and vasopressin both of which cause an elevation of BP [54]. After the discovery of captopril in the 1970s [55], other antihypertensive drugs that target components of the RAAS cascade



were developed [49,56]. Ang II type 1 receptor blockers (ARB) emerged from this research programme; these drugs prevent the vasoconstrictive effects of Ang II by blocking its main receptor, AT1R [57]. Ang II can also activate the angiotensin type 2 receptor (AT2R), the receptor considered to be protective. In this respect, Ang II can inhibit AT1R-mediated effects by directly binding to this receptor and on the other hand, counterbalance the deleterious effects of AT1R signalling by eliciting vasodilatory, antihypertensive, proapoptotic as well as antiproliferative effects [58].

Angiotensin III (Ang III) and angiotensin IV (Ang IV) are generated from Ang II by either ACE1 and aminopeptidase A or by aminopeptidase N [23,59]. Ang III can be further cleaved by aminopeptidases N, M and B to form Ang IV [59,60]. Both Ang III and Ang IV are believed to exert their actions *via* AT1 receptors [61,62]. However, Ang III is a vasoconstrictive peptide that has higher affinity for AT2 receptors whereas Ang IV prefers the angiotensin type IV receptors (AT4R) [23,62,63]. AT4 receptors are found throughout the body, e.g. in the brain, lung and kidney tissue; these receptors are involved in cognitive and proliferative functions [63].

Angiotensin (1–9) (Ang (1–9)) releases arachidonic acid, promotes the formation of nitric oxide, increases bradykinin activity, may reduce BP *via* AT2R activation and participates in inhibiting platelet function [64–67]. Ang (1–9) can be generated from Ang I by several enzymes e.g. ACE2 [68], carboxypeptidase A or cathepsin A [64,69]. ACE2, first cloned in 2000, shares 42% sequence identity with its homologue, ACE1 [70]. ACE2 has been detected in various organs such as heart, kidney, lung, liver and interestingly in the human eye [68,71,72]. ACE2 converts Ang I into Ang (1–9) and Ang II into Ang (1–7) [68,73–76]. The enzymatic activity of ACE2 is regulated by chloride ions similarly as in ACE1 activity [33]. However, ACE2 activity is not affected by ACE inhibitors, i.e. its activity is not blocked by the commonly used antihypertensive medications, which explains why the ACE2-Ang(1–7)-MasR axis is considered as a novel target in cardiovascular drug research [73,77].

Ang (1–7) is known to have biological functions opposite to those of Ang II [60]; it can be metabolised from Ang II by ACE2, prolyl-endopeptidase and prolyl-carboxypeptidase [23,78] or from Ang (1–9) by ACE1 and NEP [74] or directly from Ang I or from prohormone Ang (1–12), bypassing the biosynthesis of the vasoconstrictor Ang II [78,79]. Ang (1–7), a counter-regulator of Ang II, exerts its vasodilating and antiproliferative effects *via* yet another receptor type; MasR

[67,80]. Ang (1–7) may also bind to AT1 and AT2 receptors although it displays considerable AT2R selectivity over AT1R [62,67,80]. MasR, a G-protein coupled receptor has been found in several organs including kidney, heart, brain and human eye [81]. Since Ang (1–7) possesses anti-arrhythmogenic, antithrombogenic, growth-inhibitory and vasoconstriction inhibitory properties, it can be considered as a protective and key counter-regulatory component of the RAAS cascade [75,82,83]. These beneficial effects of Ang (1–7) on the pathology of multiple diseases such as hypertension [77,78,80,84] and diabetic nephropathy [85–88] have only recently been discovered, opening new possibilities for further drug development.

Ang (1–7) can then be further metabolized into shorter angiotensin peptides such as the newly discovered antiproliferative and vasodilating peptide Ang (3, 4) [89] or it can be decarboxylated into alamandine (Ala-Arg-Val-Tyr-Ile-His-Pro), which also has antiproliferative and vasodilating properties [90–93]. Recently, the newly discovered compound, alamandine, has been postulated to counterbalance the harmful effects of the ACE1–Ang II–AT1R axis both systemically and locally. Ang (3–4) exerts its antihypertensive and natriuretic effects *via* AT2 receptors [89] whereas alamandine mediates its vasodilating actions *via* yet another receptor type Mas-related G-protein coupled receptor D (MrgD) [94,95]. These two novel components of RAAS, alamandine and its receptor MrgD, are similar in function and in structure to Ang (1–7) and its receptor MasR, constituting a new protective axis of RAAS [92,93,96]. Ang (3–4) can also be seen as one of the protective peptides produced by the RAAS cascade since it can inhibit ACE1, elevate Ang (1–7) levels and reduce the levels of both Ang II and aldosterone in plasma [89]. This short peptide is also able to permeate extensively through intestinal cells and is known to be highly resistant to hydrolysis. For these reasons, it has been suggested that Ang (3–4) could well be effective when administered orally—another new aspect of RAAS giving drug developers new targets on which to focus [89]. Whether Ang (3–4) or alamandine will have significant therapeutic roles in other organs remains to be resolved.

A mineralocorticoid hormone, aldosterone, is the end product of an RAAS cascade [97]. Ang II as well as Ang III stimulate aldosterone release from adrenal glands which is also the main site of aldosterone synthesis [97,98]. After secretion, aldosterone exerts its effects on sodium and fluid homeostasis *via* the mineralocorticoid receptor (MR) [21]. However, another

endogenous ligand, cortisol, binds to MR with much higher affinity than aldosterone [99]. If the MR is to be activated by its specific ligand aldosterone, then the 11 $\beta$ -hydroxysteroid dehydrogenase type 2 (HSD2) enzyme must be present since it converts cortisol into cortisone, which has much reduced affinity for MR. Together with Ang II, aldosterone stimulates fibrosis, inflammation, cell proliferation, neovascularization and oxidative stress [21,97].

### Tissue RAAS

Today, the importance of RAAS as a localized system capable of affecting the functions of individual organs is well recognized. These tissue-specific regulatory systems have been detected in many organs such as brain, heart, intestine and eye, proving that RAAS is not simply an endocrine but also an autocrine system [100,101]. Ganten et al. [102] were the first to observe that RAAS is not only an endocrine circulatory system but also an organ-specific system that has important regulatory roles at the tissue level, e.g. eliciting cell growth, proliferation and protein synthesis [23,45,101]. Based on the origin of Ang II, local RAAS can be described either as extrinsic or intrinsic: in the former case, Ang II originates from the circulation while in the latter case, Ang II is synthesized locally [60]. As some local RAA systems are reliant on systemic RAAS while other RAA systems function independently of the systemic RAAS, producing their own components locally, RAAS can be considered as a key proteolytic system that possesses intracrine, autocrine, paracrine as well as endocrine functions in the human body [45,60,101].

The ophthalmic literature focussing on RAAS dates back to 1977 when Igic et al. described ACE1 activity in homogenates derived from retina [103]. Now, all of the key components of RAAS including ACE1-Ang II-AT1R and ACE2-Ang(1-7)-MasR have been identified in retinal as well as non-retinal structures of the human eye [71,81,100,104]. So far, neither Ang IV nor AT4R have been identified in the human eye. Table 1 summarizes the distribution of RAAS components in non-retinal structures of the human eye.

As the blood-ocular barrier prevents circulatory angiotensinogen, Ang I and Ang II from passing into the intraocular compartment and since the Ang I and Ang II concentrations in retina, choroid and anterior uveal tract have been shown to be higher than in plasma, it is believed that RAAS components in ocular tissue must be produced locally, i.e. there must be an intrinsic ocular RAAS [16]. While the local ocular RAAS

has been linked to different eye diseases such as DR, AMD, ROP and glaucoma, its overall significance in ocular (patho)physiology is still somewhat unclear [15,16,21,100,104]. In animal models, RAAS has also been linked to uveitis [132-138] and cataract [139-141]. Furthermore, ocular RAAS has been suggested to play a role in the regulation of IOP as it can alter AH dynamics [101,112,142]. Moreover, systemic administration of antihypertensive drugs acting through RAAS, such as ACE inhibitors [143], and ARB blockers [144] as well as topical administration of ACE inhibitors [145,146], ARB blockers [147,148] and renin inhibitors [149], have been shown to reduce IOP.

### RAAS involvement in AH dynamics and IOP

#### Glaucoma

Glaucoma, with its numerous subtypes, is a multifactorial optic neuropathy that leads to death of retinal ganglion cells and the loss of retinal neurons thus causing an irreversible disturbance of vision [150,151]. This devastating eye disease can be challenging to diagnose, as glaucoma can be asymptomatic for a long period of time [152]. Even though IOP is one of the best known risk factors for glaucoma, there are many still unknown factors having an important role in the pathogenesis of neuropathy, i.e. factors evoking oxidative stress or otherwise damaging the nerve fibre layer. Not every patient diagnosed with glaucoma has an elevated IOP value nor do all patients with high IOP invariably develop glaucoma [10]. However, IOP is seen as the only modifiable risk factor for glaucoma, meaning that at present, only pressure reducing treatments have been effective in slowing down disease progression [11,12,153-155]. Increasing attention is now being paid to developing neuroprotective molecules and therapies [13,14,156].

Since the IOP depends on the balance between the formation and outflow of AH, all anti-glaucomatous treatments such as medicated eye drops, laser therapy and surgical procedures, aim to lower IOP either by decreasing AH formation or by increasing AH outflow [10-12,153-155,157] with the latter being the main mechanism of their ocular hypotensive action.

#### IOP

As AH formation is pressure-insensitive, it remains relatively constant even at high pressure conditions [158]. On the contrary, AH drainage is sensitive to pressure variations. In order to keep IOP within an acceptable physiological range, corrective adjustments need to be

**Table 1.** Renin–angiotensin–aldosterone system components described in different structures of the human eye.

Component	Eye structure	Reference	Analytical technique
Prorenin	Bulbar conjunctiva, cornea, aqueous humour, iris, ciliary body/NPE, vitreous, sclera	[105–109]	RT-PCR + IF, ICC staining, IHC staining, immune-EM, enzyme kinetic assay
Renin	Bulbar conjunctiva, cornea, iris, ciliary body/NPE, vitreous, sclera	[105,108,109]	RT-PCR + IF, IHC staining, enzyme kinetic assay, sandwich assay
AGT	Bulbar conjunctiva, cornea, aqueous humour, iris, ciliary body/NPE, vitreous, sclera	[105,110–112]	RT-PCR + IF, SDS-PAGE + nano-ESI-LC/MS/MS, gel electrophoresis + immunoblotting, IHC staining, PCR
ACE1	Bulbar conjunctiva, cornea, trabecular meshwork, aqueous humour, iris, ciliary body/NPE, tears/lacrimal gland, vitreous, optic nerve head, sclera	[71,105,113–121]	ELISA, RT-PCR + IF, IHC staining, enzyme activity assay, inhibitor binding assay, solid-phase chemiluminescence immunoassay, 2D gel electrophoresis + ESI-MS-MS + LCQ, Sep-Pak + HPLC + RIA
ACE2	Aqueous humour	[71]	ELISA
HSD1	Cornea, trabecular meshwork, ciliary body/NPE, lens	[122–124]	mRNA hybridization + silver grains counting, IHC staining + RT-PCR, IF-ISH
HSD2	Cornea, trabecular meshwork, ciliary body/NPE, lens	[122,124,125]	mRNA hybridization + silver grains counting, IHC staining
Ang I	Aqueous humour, iris, ciliary body/NPE, vitreous	[126,127]	Sep-Pak + HPLC + RIA, HPLC
Ang II	Bulbar conjunctiva, cornea, trabecular meshwork, aqueous humour, iris, ciliary body/NPE, vitreous, optic nerve head	[113,126–128]	IHC staining, Sep-Pak + HPLC + RIA, HPLC, RIA, ICC staining + confocal imaging
Ang (1–7)	Trabecular meshwork, aqueous humour, ciliary body/NPE	[71,81,128]	ELISA, IHC staining + light and fluorescent microscopy, ICC staining + confocal imaging
Aldosterone (P)RR	Lens Bulbar conjunctiva, cornea, iris, ciliary body/NPE, sclera	[129] [105]	RIA RT-PCR + IF
AT, unknown subtype	Iris, ciliary body/NPE	[130,131]	radioligand binding assay, angiotensin-evoked contractions antagonised by 8-Ala-Ang II in a competitive manner
AT1R	Bulbar conjunctiva, cornea, iris, ciliary body/NPE, optic nerve head	[105,112,128]	RT-PCR + IF, PCR, competitive membrane-binding assay, ICC staining + confocal imaging
AT2R	Iris, ciliary body/NPE, optic nerve head	[128]	competitive membrane-binding assay, ICC staining + confocal imaging
MasR	Cornea, trabecular meshwork, ciliary body/NPE	[81]	IHC staining + light and fluorescent microscopy
MR	Cornea, trabecular meshwork, ciliary body/NPE, lens	[121–124]	mRNA hybridization + silver grains counting, IHC staining, RT-PCR

Table modified and updated from the table published by Holappa et al. [104]. ACE1, -2: Angiotensin converting enzyme 1, -2; AGT: Angiotensinogen; Ang I, -II: Angiotensin I, -II; Ang (1–7): Angiotensin (1–7); AT1R, -2R, -4R: Angiotensin II type 1, 2, 4 receptor; EM: electron microscope; HSD-1, -2: 11 $\beta$ -hydroxysteroid dehydrogenase type 1, -2; HPLC: high performance liquid chromatography; ICC: immunocytochemistry; ICH: immunohistochemistry; IF: indirect immunofluorescence; ISH: *in situ* hybridization; MasR: Mas receptor; MS: mass spectrometry; MR: mineralocorticoid receptor; NPE: non-pigmented ciliary epithelium; (P)RR: (pro)renin receptor; RIA: radioimmunoassay.

made to resistance to AH outflow rather than lowering AH formation [158,159]. AH is a mixture of different growth factors, proteins, amino acids, electrolytes, cytokines as well as organic and inorganic solutes [160–164]. AH is continuously produced by the ciliary body [165] in order to feed the non-vascularized ocular structures [166] and it is removed from the anterior chamber through the trabecular, uveoscleral or the uveolymphatic pathways [167]. The AH circulation removes excretory products, transports neurotransmitters and it also enables mediators and inflammatory cells to circulate in the eye [166,168]. An optimal IOP is necessary to maintain the correct shape of the human eye as well as sustaining its optical and refractive properties [169–172]. AH flow against resistance creates an IOP of about 15  $\pm$  5 mmHg [165,169,170].

However, postural variations [173], physical exercise [174–177], sleeping, aging and some systematic diseases such as diabetes can cause variations in IOP [167]. The diurnal fluctuation of IOP, which is about 5 mmHg in healthy subjects, may also be linked to glucocorticoid secretion as the highest level of cortisol is usually detected in the morning [178].

The epithelial cells lining the ciliary body produce AH, which is secreted into the posterior chamber through active secretion, diffusion or ultrafiltration [166]. Diffusion and ultrafiltration, neither of which require cellular activity or energy, account for only 10–20% of all AH formation [166]. Hydrolysis of adenosine triphosphate (ATP) by Na<sup>+</sup>/K<sup>+</sup> ATPase produces enough energy to allow the active and selective secretion and transport of ions and molecules across the



epithelium against a concentration gradient [166,169]. In addition, active transport of  $\text{Na}^+$  into the posterior chamber causes water flow from the stromal pool into the posterior chamber [179,180].

From the posterior chamber, AH flows between the lens and the iris into the anterior chamber after which it can be excreted either through the trabecular or uveoscleral pathways. A novel so-called uveolymphatic pathway has also been described, which may even be a target for new glaucoma treatments [172,181]. In addition, AH can exit the eye *via* iris vessels, corneal endothelium and anterior vitreous body [181,182] but their significance to AH dynamics is minimal. In the trabecular pathway, which is the main route of drainage, AH flows through the porous, AH filtering trabecular meshwork, the endothelial lining of Schlemm's canal itself, the collecting channels and aqueous veins into the circulatory system [158,166,172]. This process is known to be passive with the AH movement being driven by the pressure gradient (IOP) [168,181,183]. The actin cytoskeleton and the adhesions of trabecular meshwork cells affect the fluid outflow but the rate limiting step is considered to be the flow through the endothelium in the inner wall of Schlemm's canal [168,184–188].

The uveoscleral and the novel uveolymphatic pathways together carry approximately 10% of all AH outflow [181]. In the uveoscleral pathway, AH drains through the ciliary muscle and supraciliary space across the posterior sclera into the choroidal vessels and systemic circulation [189–191]. AH drainage through the uveoscleral pathway does not rely on a pressure gradient [191,192]. This drainage route may also undergo age-dependent changes [181,191,192]. The uveolymphatic pathway is located in channels of the ciliary body stroma and in the intestinal space between ciliary muscle bundles [193]. This route of drainage is thought to function as a backup system for AH drainage as most of the AH is disposed *via* trabecular or uveoscleral routes [193]. However, as mentioned before, this route of drainage may be a new target for anti-glaucoma drugs.

### **The effects of RAAS components on IOP**

The complex aetiology of glaucoma complicates the development of effective therapies [3,10]. Interestingly, RAAS components have been identified in the ocular structures involved in AH formation and drainage. Multiple animal experiments as well as human studies provide support for the concept that RAAS inhibiting drugs could be potential anti-glaucomatous drugs in

the future, as ACE inhibitors [143,145,146,194], ARBs [144,147,148] and renin inhibitors [149] all are able to improve AH outflow, thus lowering IOP. In human studies, a topically administered ACE inhibitor (SCH 33861) [195] and orally administered ACE inhibitor, captopril [143] reduced IOP significantly. The observed effect of captopril on IOP was due to increased AH outflow [143]. Furthermore, AT1R-blockade by oral losartan for primary open angle glaucoma patients with or without hypertension was shown to significantly increase AH outflow and lower IOP in all patients with a mean reduction of 16%, even though the BP reduction was only evident in subjects with arterial hypertension [144].

The ability of topically administered RAAS inhibitors to lower IOP in both normotensive and hypertensive eyes has been demonstrated in multiple animal studies. In anaesthetized monkeys, a topically applied 0.3% solution of a renin inhibitor (ABBOTT-64662) commonly known as enalkiren, lowered IOP [149]. Similarly, there was a reduction in IOP in unanesthetized rabbits at 90 min after topical administration of 0.1 and 0.3% solutions of enalkiren. No alterations in systemic BP and heart rate were observed during that study [149]. In African Green monkeys, 0.0005–0.5% solution of enalaprilat, the bioactive metabolite of the pro-drug enalapril, significantly lowered IOP [196]. Furthermore, in acute and chronic rabbit models of ocular hypertension, topical administration of ACE inhibitors enalaprilat, ramiprilat and fosinopril promoted time-dependent reduction of IOP for over 4 h. The observed effect on IOP was comparable to that achievable with betaxolol and pilocarpine whereas the use of enalapril and ramipril, which are both prodrugs, did not affect IOP [145]. However, it can be speculated, if the duration of observation in the previous study was long enough in order for a prodrug to exert clear effects on IOP, i.e. another study found a significant reduction in IOP caused by enalapril maleate in conscious normotensive rabbits at 10 h after its topical application [197]. In the same study, a maximum decline in IOP with 1 and 2.9% enalaprilat solutions was first observed at 4 h after administration with a duration of action exceeding 10 h. The ability of topical enalaprilat and losartan to reduce significantly IOP has also been described in normotensive and hypertensive rat eyes [198,199]. In canine eyes, an ACE inhibitor, spiraprilate (SCH 33861), was shown to lower IOP and this reduction in IOP levels was also associated with a significant reduction in serum ACE activity and a slight decrease in aqueous ACE [200]. As ACE inhibitors in general lower BP by causing



vasodilatation, they may suppress AH production as secretory processes in ciliary body are known to be blood flow dependent i.e. AH production is impaired when blood flow is reduced below a critical level [201]. Since ACE inhibitors not only decrease Ang II levels in AH but also inhibit bradykinin breakdown, which leads to enhanced prostaglandin synthesis, this latter property could also improve AH drainage through uveoscleral outflow, resulting in IOP lowering [127,196,202–204]. By preventing the breakdown of bradykinin, ACE inhibitors also promote vasodilatation through increased nitric oxide formation and decreased endothelin-1 synthesis and cause an inactivation of reactive oxygen species while inhibiting prooxidative mechanisms within the vasculature [205–207]. As NO has IOP reducing abilities [208], dual-acting medications that act as ACE inhibitors and NO donors could potentially effectively lower IOP [209].

Since MasR and ACE2 are expressed in ocular tissues (see Table 1), the IOP lowering properties of the MasR activating heptapeptide Ang (1–7) and the ACE2 activating diminazene aceturate (DIZE) have been studied, with promising outcomes [94,210–214]. Topically administered Ang (1–7) achieved a significant IOP reduction that was completely blocked by the MasR antagonist (A-779), minimally inhibited by a non-peptide selective AT2R antagonist (PD123319) and without any inhibition by AT1R antagonist (olmesartan) [210]. Interestingly, however, Ang (1–7) injections delivered either intracamerally or intravitreally, did not promote AH outflow. Rats with experimentally induced ocular hypertension showed a significant decrease in IOP, less retinal ganglion cell death as well as reduced optic nerve degeneration when treated with chitosan inserts that released ACE2 continuously activating DIZE [215]. In contrast to Ang (1–7), Ang II has mainly negative effects on human eye although some results are controversial. In rabbits and monkeys, intracameral injections of Ang II have been shown to reduce AH outflow [202,216]. The negative effect of Ang II on AH outflow was blocked by treatment with an AT1R antagonist but not with an AT2R antagonist; similarly in rabbits, intracameral injections of an AT1R antagonist elevated uveoscleral outflow by 24% [210].

As described earlier, ARBs can, at least to some extent, increase uveoscleral outflow. More importantly perhaps, ARBs have been claimed to suppress the cell death of retinal ganglion cells independently of their IOP-lowering properties [217–219]. Orally administered candesartan has been shown to protect against the thinning of the ganglion cell complex and prevent the

progressive loss of retinal ganglion cell death in a mouse model of normotensive glaucoma (NTG) [219] as well as in rats with induced chronic glaucoma [218]. In addition, in mice with elevated IOP, treatment with losartan has been described to exert neuroprotective effects on retinal ganglion cells [217]. In a recent study, the IOP lowering and neuroprotective effects of three different systemically administered ARBs, losartan, irbesartan and telmisartan were studied [220]. BP was significantly lowered by all three ARBs when compared to the vehicle control, whereas IOP was significantly reduced by irbesartan and telmisartan but not by losartan probably due to non-equipotent dosages. In the same study, pSmad2 immunohistochemistry was performed on sagittal sections of eyes to investigate the effect of ARBs on TGF $\beta$  signalling in that organ. In mice fed with normal chow, pSmad2 was detected in the inner nuclear layer of the retina and in the retinal ganglion cell layer, evidence for the presence of TGF $\beta$  signalling in the inner retina. Only in mice treated with telmisartan in the feed, was pSmad2 fluorescence reduced in the retinal ganglion cell layer whereas in mice treated with losartan and irbesartan, no significant effect was detected. Interestingly, systemic administration of aldosterone has been claimed to evoke a dose-dependent progressive loss of retinal ganglion cells [221,222]. In NTG rats, systemically administered aldosterone caused a loss of retinal ganglion cells, thinning of the retinal nerve fibre layer and optic nerve cupping. In addition, treatment with a mineralocorticoid receptor blocker, spironolactone, improved retinal ganglion cell survival independently of any effects on IOP [222]. All of these studies support the concept of aldosterone's role in RAAS at least to some extent, in the regulation of neurodegeneration. Moreover, the dual ability of ARBs to lower IOP and act as neuroprotective agents is promising when searching for new effective ways to treat glaucoma [219,220,223].

To conclude, the IOP is the sum of AH formation and outflow and most of the AH drainage occurs through the trabecular pathway. The extracellular matrix (ECM) in the trabecular meshwork contributes considerably to resistance to AH outflow and therefore disturbances in ECM homeostasis can increase outflow resistance and lead to elevated IOP and to the development of glaucomatous eyes [224]. Hence, it has been speculated that the positive effects of RAAS blockade on IOP may be mediated through a restoration of the homeostasis in the ECM. The interplay between RAAS and growth factors as well as the presence of regulatory proteins in the ECM of the

trabecular meshwork have been described. AT1R activation stimulates transforming growth factor  $\beta$  (TGF- $\beta$ ) signalling which in turn augments connective tissue growth factor (CTGF) expression, suppresses Wnt/ $\beta$  catenin signalling and reduces bone morphogenetic protein (BMP) activity, all of which lead to alterations in ECM protein gene expression and hence to ECM deposition [224]. TGF- $\beta$  also reduces matrix metalloproteinase expression *via* the stimulation of plasminogen activator inhibitor 1 (PAI-1) thus actively abolishing ECM remodelling. The AT4R activation by Ang II promotes PAI-1 release and for that reason, Ang II inhibits the breakdown of ECM in the trabecular meshwork. Ang II can also promote collagen synthesis *in vivo* and augment cell proliferation in the trabecular meshwork [225]. ACE 2, the enzyme that cleaves Ang II into Ang (1–7), is able to suppress the profibrotic effects of Ang II while enhancing Ang (1–7) signalling through MasR [224]. Disturbances in the interplay of the two main axes of RAAS may indeed exert detrimental effects in ECM homeostasis, observed as changes in IOP values.

Mineralocorticoid antagonists (RU 26752 and ZK 91587) seem to mainly affect AH formation rather than drainage [226,227] although MR, HSD1 and HSD2 have been described in the ciliary body as well as in trabecular meshwork (see Table 1). It remains to be resolved whether aldosterone can affect the trabecular meshwork. In most glaucoma patients, the systemic application of mineralocorticoids into the eye does not affect IOP [228]. In some cases, however, the systemic administration of mineralocorticoids may greatly increase IOP [226]. Sodium transport across the ciliary body NPE/PE bi-layer and hence AH formation may be partly regulated by HSD1 activity as oral treatment with an HSD1 inhibitor (carbenoxolone) reduced IOP by 17.5% [124]. In a randomized, placebo-controlled study, orally administered carbenoxolone reduced IOP by 10% in patients with ocular hypertension [123].

For years, it has been suggested that there are possible connections and even an interplay between BP and IOP, and hence between hypertension and glaucoma [229]. As the RAAS operates at the systemic level as well as at the tissue level, components of this key proteolytic pattern have been of special interest. There are reports that Ang II disturbs sodium handling in ciliary and renal tubular epithelium, which could explain the possible linkage between hypertension and glaucoma [230]. On the other hand, hypertension can affect the blood supply to the optic nerve by causing microvascular damage and defects in the autoregulation of the posterior ciliary circulation whereas hypotension induced by

antihypertensive medication may harm the optic nerve fibres [231–233].

Only a few population-based studies have been published during the last couple of years aimed at determining possible associations between systemic cardiovascular medication and IOP [229,234,235]. The results of these studies are somewhat contradictory and not able to confirm this relationship. The first published study conducted in a British population stated that the use of systemic  $\beta$ -blockers and nitrates was independently associated with lower IOP values [235]. In the second study performed in a multiethnic Asian population, the systemic use of  $\beta$ -blockers was associated independently with lower IOP values whereas the systemic use of ACE inhibitors, ARBs, statins and sulfonylureas was found to elevate the IOP values [234]. In fact, the observed associations have been modest at best. In the third and newest population-based study, the Gutenberg Health Study conducted in Germany, none of the cardiovascular medications and especially neither the selective nor non-selective systemic use of  $\beta$ -blockers was associated with lower IOP in a statistically significant manner [229].

Nonetheless, there is accumulating evidence for a local ocular RAAS involvement in IOP homeostasis, neuroprotection and ocular pathology, suggesting that a local ocular RAAS may play a role in AH dynamics, IOP and hence at least to some extent, in the pathology of glaucoma.

## Conclusion

Today, RAAS is recognized as a key proteolytic system that operates both at the systemic and tissue level, controlling a wide spectrum of (patho)physiological activities. Since its pivotal role in BP and fluid balance regulator is recognized, the research on RAAS is now concentrating on its role in the physiology in different organs including the human eye. RAAS components have been detected in various structures in the eye, hinting at the involvement of intraocular RAAS in different eye diseases such as DR, age-regulated macular degeneration, ROP and glaucoma. Location of RAAS components in the ocular structures participating in the formation and outflow of AH makes their role in AH dynamics and IOP regulation plausible. Therefore, components of RAAS are potential targets for the development of anti-glaucomatous drugs. The presence of RAAS constituents in retina, and neuroprotective properties of RAAS antagonists without effects on IOP, suggest them as lead molecules in the search for

new effective ways to treat the whole entity of glaucoma.

## Acknowledgements

The authors thank Finska Läkaresällskapet Einar och Karin Stroems Stiftelse (HV) and Glaukooma Tukisäätiö Lux (AV). We are also grateful to Dr. Ewen MacDonald for excellent work in checking the grammar and style of the manuscript.

## Disclosure statement

No potential conflict of interest was reported by the author(s).

## Funding

The authors want to thank Finska Läkaresällskapet Einar och Karin Stroems Stiftelse (HV) and Glaukooma Tukisäätiö Lux (AV).

## References

- [1] Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. *Lancet Glob Health*. 2017;512:e1221–e1234.
- [2] Tham Y, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology*. 2014;121(11):2081–2090.
- [3] Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. *JAMA*. 2014;311(18):1901–1911.
- [4] Jonas JB, Aung T, Bourne RR, et al. Glaucoma. *Lancet*. 2017;390:2083–2093.
- [5] Wang H, Sun P, Chen Y, et al. Research progress on human genes involved in the pathogenesis of glaucoma (review). *Mol Med Rep*. 2018;181:656–674.
- [6] Miller MA, Fingert JH, Bettis DI. Genetics and genetic testing for glaucoma. *Curr Opin Ophthalmol*. 2017;28(2):133–138.
- [7] Wiggs JL, Pasquale LR. Genetics of glaucoma. *Hum Mol Genet*. 2017;26(R1):R21–R27.
- [8] McMonnies CW. Glaucoma history and risk factors. *J Optom*. 2017;10(2):71–78.
- [9] Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. *Ophthalmology*. 2008;1157:1123–1129.e3.
- [10] Schmidl D, Schmetterer L, Garhöfer G, et al. Pharmacotherapy of glaucoma. *J Ocul Pharmacol Ther*. 2015;31(2):63–77.
- [11] Boland MV, Ervin AM, Friedman DS, et al. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. preventive services task force. *Ann Intern Med*. 2013;158(4):271–279.
- [12] Conlon R, Saheb H, Ahmed I. Glaucoma treatment trends: a review. *Can J Ophthalmol*. 2017;52(1):114–124.
- [13] Bucolo C, Platania CBM, Drago F, et al. Novel therapeutics in glaucoma management. *Curr Neuropharmacol*. 2018;16(7):978–992.
- [14] Guymer C, Wood JP, Chidlow G, et al. Neuroprotection in glaucoma: recent advances and clinical translation. *Clin Experiment Ophthalmol*. 2019;47(1):88–105.
- [15] Choudhary R, Kapoor M, Singh A, et al. Therapeutic targets of renin-angiotensin system in ocular disorders. *J Curr Ophthalmol*. 2016;:1–10.
- [16] Igić R. Four decades of ocular renin-angiotensin and kallikrein-kinin systems (1977–2017). *Exp Eye Res*. 2018;166:74–83.
- [17] Kurihara T, Ozawa Y, Ishida S, et al. Renin-angiotensin system hyperactivation can induce inflammation and retinal neural dysfunction. *Int J Inflamm*. 2012;2012:1–14.
- [18] Marin Garcia PJ, Marin-Castaño ME. Angiotensin II-related hypertension and eye diseases. *WJC*. 2014;6(9):968–984.
- [19] Nath M, Chandra P, Halder N, et al. Involvement of renin-angiotensin system in retinopathy of prematurity - a possible target for therapeutic intervention. *Plos One*. 2016;11(12):e0168809.
- [20] Kanda A, Ishida S. (Pro)renin receptor: involvement in diabetic retinopathy and development of molecular targeted therapy. *J Diabetes Investig*. 2019;10(1):6–17.
- [21] Wilkinson-Berka JL, Suphachimol V, Jerome JR, et al. Angiotensin II and aldosterone in retinal vasculopathy and inflammation. *Exp Eye Res*. 2019;187:107766.
- [22] Kunikullaya U K, Ananthkrishnan V, Goturu J. Robert Tigerstedt and the discovery of renin — a revisit. *Int J Cardiol*. 2012;158(1):1–5.
- [23] Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. *J Intern Med*. 2008;264(3):224–236.
- [24] Tigerstedt R, Bergman P. Niere und Kreislauf. *Scand Arch Physiol*. 1898;8(1):223–271.
- [25] Paulis L, Unger T. Novel therapeutic targets for hypertension. *Nat Rev Cardiol*. 2010;7(8):431–441.
- [26] Ferrario CM. ACE2: more of Ang-(1-7) or less Ang II? *Curr Opin Nephrol Hypertens*. 2011;20(1):1–6.
- [27] Ferreira AJ, Santos RA, Bradford CN, et al. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. *Hypertension*. 2010;55(2):207–213.
- [28] Paz Ocaranza M, Riquelme JA, García L, et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. *Nat Rev Cardiol*. 2020;17(2):116–129.
- [29] Forrester SJ, Booz GW, Sigmund CD, et al. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. *Physiol Rev*. 2018;98(3):1627–1738.
- [30] Wu C, Lu H, Cassis LA, et al. Molecular and pathophysiological features of angiotensinogen: a mini review. *N Am J Med Sci*. 2011;4(4):183–190.
- [31] Castrop H, Höcherl K, Kurtz A, et al. Physiology of kidney renin. *Physiol Rev*. 2010;90(2):607–673.

Q1  
Q2

1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060



- 1061 [32] Ferrão FM, Lara LS, Lowe J. Renin-angiotensin sys- 1114  
 1062 tem in the kidney: what is new? *World J Nephrol.* 1115  
 1063 2014;33:64–76. 1116  
 1064 [33] Guang C, Phillips RD, Jiang B, et al. Three key pro- 1117  
 1065 teases–angiotensin-I-converting enzyme (ACE), ACE2 1118  
 1066 and renin - within and beyond the renin-angiotensin 1119  
 1067 system. *Arch Cardiovasc Dis.* 2012;105(6-7):373–385. 1120  
 1068 [34] Nguyen G, Delarue F, Burcklé C, et al. Pivotal role of 1121  
 1069 the renin/prorenin receptor in angiotensin II produc- 1122  
 1070 tion and cellular responses to renin. *J Clin Invest.* 1123  
 1071 2002;109(11):1417–1427. 1124  
 1072 [35] Henrikus M, Gonzalez AA, Prieto MC. The prorenin 1125  
 1073 receptor in the cardiovascular system and beyond. *Am 1126  
 1074 J Physiol Heart Circ Physiol.* 2018;314(2):H139–H145. 1127  
 1075 [36] Bernstein KE, Ong FS, Blackwell WB, et al. A modern 1128  
 1076 understanding of the traditional and nontraditional 1129  
 1077 biological functions of angiotensin-converting 1130  
 1078 enzyme. *Pharmacol Rev.* 2013;65(1):1–46. 1131  
 1079 [37] Boucher R, Demassieux S, Garcia R, et al. Tonin, angio- 1132  
 1080 tensin II system. A review. *Circ Res.* 1977;41(4):26–29. 1133  
 1081 [38] Arakawa K. Serine protease angiotensin II systems. *J 1134  
 1082 Hypertens Suppl.* 1996;14(5):S3–S7. 1135  
 1083 [39] Maruta H, Arakawa K. Confirmation of direct angio- 1136  
 1084 tensin formation by kallikrein. *Biochem J.* 1983; 1137  
 1085 213(1):193–200. 1138  
 1086 [40] Tonnesen MG, Klempner MS, Austen KF, et al. 1139  
 1087 Identification of a human neutrophil angiotensin II- 1140  
 1088 generating protease as cathepsin G. *J Clin Invest.* 1141  
 1089 1982;69(1):25–30. 1142  
 1090 [41] Becari C, Oliveira EB, Salgado MC. Alternative pathways 1143  
 1091 for angiotensin II generation in the cardiovascular sys- 1144  
 1092 tem. *Braz J Med Biol Res.* 2011;44(9):914–919. 1145  
 1093 [42] Urata H, Healy B, Stewart RW, et al. Angiotensin II- 1146  
 1094 forming pathways in normal and failing human 1147  
 1095 hearts. *Circ Res.* 1990;66(4):883–890. 1148  
 1096 [43] Urata H, Kinoshita A, Misono KS, et al. Identification 1149  
 1097 of a highly specific chymase as the major angioten- 1150  
 1098 sin II-forming enzyme in the human heart. *J Biol 1151  
 1099 Chem.* 1990;265(36):22348–22357. 1152  
 1100 [44] Uehara Y, Miura S-i, Yahiro E, et al. Non-ACE path- 1153  
 1101 way-induced angiotensin II production. *CPD.* 2013; 1154  
 1102 19(17):3054–3059. 1155  
 1103 [45] Miyazaki M, Takai S. Tissue angiotensin II generating 1156  
 1104 system by angiotensin-converting enzyme and chy- 1157  
 1105 mase. *J Pharmacol Sci.* 2006;100(5):391–397. 1158  
 1106 [46] Resende MM, Mill JG. Alternate angiotensin II-form- 1159  
 1107 ing pathways and their importance in physiological 1160  
 1108 or physiopathological conditions. *Arq Bras Cardiol.* 1161  
 1109 2002;78(4):425–438. 1162  
 1110 [47] Igić R, Behnia R. Properties and distribution of angio- 1163  
 1111 tensin I converting enzyme. *CPD.* 2003;9(9):697–706. 1164  
 1112 [48] Lew RA. The zinc metallopeptidase family: new faces, 1165  
 1113 new functions. *PPL.* 2004;11(5):407–414. 1166  
 1114 [49] Atlas SA. The renin-angiotensin aldosterone system: 1167  
 1115 pathophysiological role and pharmacologic inhib- 1168  
 1116 ition. *JMCP.* 2007;13(8 Supp B):9–20. 1169  
 1117 [50] Wong J, Patel RA, Kowey PR. The clinical use of 1170  
 1118 angiotensin-converting enzyme inhibitors. *Progr 1171  
 1119 Cardiovasc Dis.* 2004;47(2):116–130. 1172  
 1120 [51] Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II 1173  
 1121 and vascular inflammation. *Med Sci Monit.* 2005; 1174  
 1122 11(6):RA194–205. 1175  
 1123 [52] Mehta PK, Griendling KK. Angiotensin II cell signal- 1176  
 1124 ing: physiological and pathological effects in the car- 1177  
 1125 diovascular system. *Am J Physiol Cell Physiol.* 2007; 1178  
 1126 292:82–97. 1179  
 1127 [53] Higuchi S, Ohtsu H, Suzuki H, et al. Angiotensin II 1180  
 1128 signal transduction through the AT1 receptor: novel 1181  
 1129 insights into mechanisms and pathophysiology. *Clin 1182  
 1130 Sci.* 2007;112(8):417–428. 1183  
 1131 [54] Culman J, Höhle S, Qadri F, et al. Angiotensin as 1184  
 1132 neuromodulator/neurotransmitter in central control 1185  
 1133 of body fluid and electrolyte homeostasis. *Clin Exp 1186  
 1134 Hypertens.* 1995;17(1-2):281–293. 1187  
 1135 [55] Ondetti MA, Rubin B, Cushman DW. Design of spec- 1188  
 1136 ific inhibitors of angiotensin-converting enzyme: 1189  
 1137 new class of orally active antihypertensive agents. 1190  
 1138 *Science.* 1977;196(4288):441–444. 1191  
 1139 [56] Ferrario CM, Mullick AE. Renin angiotensin aldoster- 1192  
 1140 one inhibition in the treatment of cardiovascular dis- 1193  
 1141 ease. *Pharmacol Res.* 2017;125(Pt A):57–71. 1194  
 1142 [57] Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin 1195  
 1143 II receptors and angiotensin II receptor 1196  
 1144 antagonists. *Pharmacol Rev.* 1993;45(2):205–251. 1197  
 1145 [58] Schulman I, Raj L. The angiotensin II type 2 recep- 1198  
 1146 tor: what is its clinical significance?. *Curr Sci.* 2008; 1199  
 1147 10(3):188–193. 1200  
 1148 [59] Vaajanen A, Luhtala S, Oksala O, et al. Does the 1201  
 1149 renin-angiotensin system also regulate intra-ocular 1202  
 1150 pressure?. *Ann Med.* 2008;40(6):418–427. 1203  
 1151 [60] Ribeiro-Oliveira A, Nogueira AI, Pereira RM, et al. The 1204  
 1152 renin-angiotensin system and diabetes: an update. 1205  
 1153 *Vasc Health Risk Manag.* 2008;44:787–803. 1206  
 1154 [61] Li XC, Campbell DJ, Ohishi M, et al. AT1 receptor- 1207  
 1155 activated signaling mediates angiotensin IV-induced 1208  
 1156 renal cortical vasoconstriction in rats. *Am J Physiol 1209  
 1157 Renal Physiol.* 2006;290(5):F1024–1033. 1210  
 1158 [62] Bosnyak S, Jones E, Christopoulos A, et al. Relative 1211  
 1159 affinity of angiotensin peptides and novel ligands at 1212  
 1160 AT1 and AT2 receptors. *Clin Sci.* 2011;121(7):297–303. 1213  
 1161 [63] Chai SY, Fernando R, Peck G, et al. The angiotensin 1214  
 1162 IV/AT4 receptor. *Cell Mol Life Sci.* 2004;61(21): 1215  
 1163 2728–2737. 1216  
 1164 [64] Jackman HL, Massad MG, Sekosan M, et al. 1217  
 1165 Angiotensin 1-9 and 1-7 release in human heart: role 1218  
 1166 of cathepsin A. *Hypertension.* 2002;39(5):976–981. 1219  
 1167 [65] Ocaranza MP, Michea L, Chiong M, et al. Recent 1220  
 1168 insights and therapeutic perspectives of angiotensin- 1221  
 1169 (1-9) in the cardiovascular system. *Clin Sci.* 2014; 1222  
 1170 127(9):549–557. 1223  
 1171 [66] Mogielnicki A, Kramkowski K, Chabielska E, et al. 1224  
 1172 Angiotensin (1-9) influences hemodynamic and 1225  
 1173 hemostatic parameters in rats. *Pol J Pharmacol.* 1226  
 1174 2003;55:503–504. 1227  
 1175 [67] McKinney CA, Fattah C, Loughrey CM, et al. 1228  
 1176 Angiotensin-(1-7) and angiotensin-(1-9): function in 1229  
 1177 cardiac and vascular remodelling. *Clin Sci.* 2014; 1230  
 1178 126(12):815–827. 1231  
 1179 [68] Donoghue M, Hsieh F, Baronas E, et al. A novel 1232  
 1180 angiotensin-converting enzyme-related carboxypep- 1233  
 1181 tidase (ACE2) converts angiotensin I to angiotensin 1234  
 1182 1-9. *Circ Res.* 2000;87(5):E1–9. 1235  
 1183 [69] Kokkonen JO, Saarinen J, Kovanen PT. Regulation of 1236  
 1184 local angiotensin II formation in the human heart in 1237



- the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity. *Circulation*. 1997;95(6):1455–1463.
- [70] Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. *J Biol Chem*. 2000;275(43):33238–33243.
- [71] Holappa M, Valjakka J, Vaajanen A. Angiotensin(1-7) and ACE2, “the hot spots” of renin-angiotensin system, detected in the human aqueous humor. *TOOPHTJ*. 2015;9(1):28–32.
- [72] Guy JL, Lambert DW, Warner FJ, et al. Membrane-associated zinc peptidase families: comparing ACE and ACE2. *Biochim Biophys Acta*. 2005;1751(1):2–8.
- [73] Xia H, Lazartigues E. Angiotensin-converting enzyme 2: central regulator for cardiovascular function. *Curr Hypertens Rep*. 2010;12(3):170–175.
- [74] Rice GI, Thomas DA, Grant PJ, et al. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. *Biochem J*. 2004;383(1):45–51.
- [75] Santos RA, Ferreira AJ. Angiotensin-(1-7) and the renin-angiotensin system. *Curr Opin Nephrol Hypertens*. 2007;16(2):122–128.
- [76] Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. *J Biol Chem*. 2002;277(17):14838–14843.
- [77] Dilauro M, Burns KD. Angiotensin-(1-7) and its effects in the kidney. *Sci World J*. 2009;9:522–535.
- [78] Varagic J, Trask AJ, Jessup JA, et al. New angiotensins. *J Mol Med*. 2008;86(6):663–671.
- [79] Ahmad S, Varagic J, Groban L, et al. Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate. *Curr Hypertens Rep*. 2014;16(5):1–8.
- [80] Santos RA, Ferreira AJ, Verano-Braga T, et al. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. *J Endocrinol*. 2013;216(2):R1–R17.
- [81] Vaajanen A, Kalesnykas G, Vapaatalo H, et al. The expression of Mas-receptor of the renin-angiotensin system in the human eye. *Graefes Arch Clin Exp Ophthalmol*. 2015;253(7):1053–1059.
- [82] Chappell MC. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas receptor axis: more than regulation of blood pressure. *Hypertension*. 2007;50(4):596–599.
- [83] e Silva A, Pinheiro S, Pereira R, et al. The therapeutic potential of angiotensin-(1-7) as a novel aenin-angiotensin system mediator. *MRMCMC*. 2006;6(5):603–609.
- [84] Simões e Silva AC. Pathophysiology of arterial hypertension: insights from pediatric studies. *Curr Pediatr Rev*. 2006;2:209–223.
- [85] Carey RM, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. *Trends Endocrinol Metab*. 2003;14(6):274–281.
- [86] Tikellis C, Johnston CI, Forbes JM, et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. *Hypertension*. 2003;41(3):392–397.
- [87] Senanayake PD, Bonilha VL, W Peterson J, et al. Retinal angiotensin II and angiotensin-(1-7) response to hyperglycemia and an intervention with captopril. *J Renin Angiotensin Aldosterone Syst*. 2018;19(3):147032031878932.
- [88] Verma A, Shan Z, Lei B, et al. ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy. *Mol Ther*. 2012;20(1):28–36.
- [89] Dias J, Axelband F, Lara LS, et al. Is angiotensin-(3-4) (Val-Tyr), the shortest angiotensin II-derived peptide, opening new vistas on the renin-angiotensin system? *J Renin Angiotensin Aldosterone Syst*. 2017;18(1):147032031668933.
- [90] de Souza-Neto FP, Carvalho Santuchi M, de Moraes e Silva M, et al. Angiotensin-(1-7) and alamandine on experimental models of hypertension and atherosclerosis. *Curr Hypertens Rep*. 2018;20(2):1–15.
- [91] Lautner R, Villela D, Fraga-Silva R, et al. Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. *Circ Res*. 2013;112(8):1104–1111.
- [92] Schleifenbaum J. Alamandine and its receptor MrgD pair up to join the protective arm of the renin-angiotensin system. *Front Med (Lausanne)*. 2019;6:107.
- [93] Hrenak J, Paulis L, Simko F. Angiotensin A/alamandine/MrgD axis: another clue to understanding cardiovascular pathophysiology. *IJMS*. 2016;17(7):1098.
- [94] Solinski HJ, Gudermann T, Breit A. Pharmacology and signaling of Mas-related G protein-coupled receptors. *Pharmacol Rev*. 2014;66(3):570–597.
- [95] Zhu P, Verma A, Prasad T, et al. Expression and function of Mas-related G protein-coupled receptor D and its ligand alamandine in retina. *Mol Neurobiol*. 2020;57(1):513–527.
- [96] Tetzner A, Naughton M, Gebolys K, et al. Decarboxylation of Ang-(1-7) to Ala<sup>1</sup>-Ang-(1-7) leads to significant changes in pharmacodynamics. *Eur J Pharmacol*. 2018;833:116–123.
- [97] Mirabito Colafella KM, Bovée DM, Danser A. The renin angiotensin aldosterone system and its therapeutic targets. *Exp Eye Res*. 2019;186:107680.
- [98] Plovsing RR, Simonsen JA, Bie P, et al. Effects of truncated angiotensins in humans after double blockade of the renin system. *Am J Physiol*. 2003;285(5):R981–991.
- [99] Funder JW, Pearce PT, Smith R, et al. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. *Science*. 1988;242(4878):583–585.
- [100] Giese MJ, Speth RC. The ocular renin-angiotensin system: a therapeutic target for the treatment of ocular disease. *Pharmacol Ther*. 2014;142(1):11–32.
- [101] Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. *Physiol Rev*. 2006;86(3):747–803.
- [102] Ganten D, Marquez-Julio A, Granger P, et al. Renin in dog brain. *Am J Physiol*. 1971;221(6):1733–1737.
- [103] Iqic R, Robinson C, Erdos E. Angiotensin I converting enzyme activity in the choroid plexus and in the retina. New York: Pergamon Press; 1977.

- [104] Holappa M, Vapaatalo H, Vaajanen A. Many faces of renin-angiotensin system – focus on eye. *TOOPHTJ*. 2017;11(1):122–142.
- [105] White AJ, Cheruvu SC, Sarris M, et al. Expression of classical components of the renin-angiotensin system in the human eye. *J Renin Angiotensin Aldosterone Syst*. 2015;16(1):59–66.
- [106] Sramek SJ, Wallow IH, Day RP, et al. Ocular renin-angiotensin: immunohistochemical evidence for the presence of prorenin in eye tissue. *Invest Ophthalmol Vis Sci*. 1988;29(11):1749–1752.
- [107] Wallow IH, Sramek SJ, Bindley CD, et al. Ocular renin angiotensin: EM immunocytochemical localization of prorenin. *Curr Eye Res*. 1993;12(10):945–950.
- [108] Berka JL, Stubbs AJ, Wang DZ, et al. Renin-containing Müller cells of the retina display endocrine features. *Invest Ophthalmol Vis Sci*. 1995;36(7):1450–1458.
- [109] Danser AH, van den Dorpel MA, Deinum J, et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. *J Clin Endocrinol Metab*. 1989;68(1):160–167.
- [110] Chowdhury UR, Madden BJ, Charlesworth MC, et al. Proteome analysis of human aqueous humor. *Invest Ophthalmol Vis Sci*. 2010;51(10):4921–4931.
- [111] Sramek SJ, Wallow IH, Tewksbury DA, et al. An ocular renin-angiotensin system. *Immunohistochemistry of angiotensinogen*. *Invest Ophthalmol Vis Sci*. 1992;33(5):1627–1632.
- [112] Cullinane AB, Leung PS, Ortego J, et al. Renin-angiotensin system expression and secretory function in cultured human ciliary body non-pigmented epithelium. *Br J Ophthalmol*. 2002;86(6):676–683.
- [113] Savaskan E, Löffler KU, Meier F, et al. Immunohistochemical localization of angiotensin-converting enzyme, angiotensin II and AT1 receptor in human ocular tissues. *Ophthalmic Res*. 2004;36(6):312–320.
- [114] Vita JB, Anderson JA, Hulem CD, et al. Angiotensin-converting enzyme activity in ocular fluids. *Invest Ophthalmol Vis Sci*. 1981;20(2):255–257.
- [115] Aydin E, Demir HD, Sahin S. Plasma and aqueous humor angiotensin-converting enzyme levels in patients with diabetic retinopathy. *Curr Eye Res*. 2010;35(3):230–234.
- [116] Ferrari-Dileo G, Ryan JW, Rockwood EJ, et al. Angiotensin-converting enzyme in bovine, feline, and human ocular tissues. *Invest Ophthalmol Vis Sci*. 1988;29(6):876–881.
- [117] Igić R, Kojović V. Angiotensin I converting enzyme (kininase II) in ocular tissues. *Exp Eye Res*. 1980;30(3):299–303.
- [118] Immonen I, Friberg K, Sorsila R, et al. Concentration of angiotensin-converting enzyme in tears of patients with sarcoidosis. *Acta Ophthalmol*. 2009;65(1):27–29.
- [119] Ishizaki E, Takai S, Ueki M, et al. Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. *Am J Ophthalmol*. 2006;141(1):129–134.
- [120] Nakanishi T, Koyama R, Ikeda T, et al. Catalogue of soluble proteins in the human vitreous humor: comparison between diabetic retinopathy and macular hole. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2002;776(1):89–100.
- [121] Sharma OP, Vita JB. Determination of angiotensin-converting enzyme activity in tears. A noninvasive test for evaluation of ocular sarcoidosis. *Arch Ophthalmol*. 1983;101(4):559–561.
- [122] Stokes J, Noble J, Brett L, et al. Distribution of glucocorticoid and mineralocorticoid receptors and 11 $\beta$ -hydroxysteroid dehydrogenases in human and rat ocular tissues. *Invest Ophthalmol Vis Sci*. 2000;417:1629–1638.
- [123] Rauz S, Cheung CMG, Wood PJ, et al. Inhibition of 11 $\beta$ -hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension. *QJM*. 2003;96(7):481–490.
- [124] Rauz S, Walker EA, Shackleton CHL, et al. Expression and putative role of 11 $\beta$ -hydroxysteroid dehydrogenase isozymes within the human eye. *Invest Ophthalmol Vis Sci*. 2001;429:2037–2042.
- [125] Suzuki T, Sasano H, Kaneko C, et al. Immunohistochemical distribution of 11 $\beta$ -hydroxysteroid dehydrogenase in human eye. *Mol Cell Endocrinol*. 2001;173(1-2):121–125.
- [126] Danser AH, Derx FH, Admiraal PJ, et al. Angiotensin levels in the eye. *Invest Ophthalmol Vis Sci*. 1994;35(3):1008–1018.
- [127] Osusky R, Nussberger J, Amstutz C, et al. Individual measurements of angiotensin II concentrations in aqueous humor of the eye. *Eur J Ophthalmol*. 1994;4(4):228–233.
- [128] Senanayake P, Drazba J, Shadrach K, et al. Angiotensin II and its receptor subtypes in the human retina. *Invest Ophthalmol Vis Sci*. 2007;48(7):3301–3311.
- [129] Hampl R, Stárka L, Obenberger J, et al. Content and binding of aldosterone in human ocular lens. *Endocrinol Exp*. 1984;18(1):59–64.
- [130] Lin C, Stone RA, Wax MB. Angiotensin binding sites in rabbit anterior uvea and human ciliary epithelial cells. *Invest Ophthalmol Vis Sci*. 1990;31(1):147–152.
- [131] Lograno MD, Reibaldi A. Receptor-responses in fresh human ciliary muscle. *Br J Pharmacol*. 1986;87(2):379–385.
- [132] Satofuka S, Ichihara A, Nagai N, et al. Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin. *Invest Ophthalmol Vis Sci*. 2006;47(6):2686–2692.
- [133] Kurihara T, Ozawa Y, Shinoda K, et al. Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, *via* modulating AT1R and AT2R signaling in retinal inflammation. *Invest Ophthalmol Vis Sci*. 2006;47(12):5545–5552.
- [134] Okunuki Y, Usui Y, Nagai N, et al. Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan. *Invest Ophthalmol Vis Sci*. 2009;50(5):2255–2261.
- [135] Nagai N, Oike Y, Noda K, et al. Suppression of ocular inflammation in endotoxin-induced uveitis by

1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378

- blocking the angiotensin II type 1 receptor. *Invest Ophthalmol Vis Sci.* 2005;46(8):2925–2931.
- [136] Nagai N, Noda K, Urano T, et al. Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor. *Invest Ophthalmol Vis Sci.* 2005;46(3):1078–1084.
- [137] Miyazaki A, Kitaichi N, Ohgami K, et al. Anti-inflammatory effect of angiotensin type 1 receptor antagonist on endotoxin-induced uveitis in rats. *Graefes Arch Clin Exp Ophthalmol.* 2008;246(5):747–757.
- [138] Qiu Y, Shil PK, Zhu P, et al. Angiotensin-converting enzyme 2 (ACE2) activator diminazene aceturate ameliorates endotoxin-induced uveitis in mice. *Invest Ophthalmol Vis Sci.* 2014;55(6):3809–3818.
- [139] Langade D, Rao G, Girme R, et al. In vitro prevention by ACE inhibitors of cataract induced by glucose. *Indian J Pharmacol.* 2006;38(2):107–110.
- [140] Khan SA, Choudhary R, Singh A, et al. Hypertension potentiates cataractogenesis in rat eye through modulation of oxidative stress and electrolyte homeostasis. *J Curr Ophthalmol.* 2016;28(3):123–130.
- [141] Jabłeczka A, Czaplicka E, Olszewski J, et al. Influence of selected angiotensin-converting enzyme inhibitors on alloxan-induced diabetic cataract in rabbits. *Med Sci Monit.* 2009;15(11):BR334–338.
- [142] Vaajanen A, Vapaatalo H. Local ocular renin-angiotensin system - a target for glaucoma therapy? *Basic Clin Pharmacol Toxicol.* 2011;109(4):217–224.
- [143] Costagliola C, Di Benedetto R, De Caprio L, et al. Effect of oral captopril (SQ 14225) on intraocular pressure in man. *Eur J Ophthalmol.* 1995;5(1):19–25.
- [144] Costagliola C, Verolino M, De Rosa ML, et al. Effect of oral losartan potassium administration on intraocular pressure in normotensive and glaucomatous human subjects. *Exp Eye Res.* 2000;71(2):167–171.
- [145] Shah GB, Sharma S, Mehta AA, et al. Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. *J Cardiovasc Pharmacol.* 2000;36(2):169–175.
- [146] Watkins RW, Baum T, Cedeno K, et al. Topical ocular hypotensive effects of the novel angiotensin converting enzyme inhibitor SCH 33861 in conscious rabbits. *J Ocul Pharmacol.* 1987;3(4):295–307.
- [147] Wang RF, Podos SM, Mittag TW, et al. Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes. *Exp Eye Res.* 2005;80(5):629–632.
- [148] Inoue T, Yokoyama T, Mori Y, et al. The effect of topical CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure and aqueous humor dynamics in rabbits. *Curr Eye Res.* 2001;23(2):133–138.
- [149] Giardina WJ, Kleinert HD, Ebert DM, et al. Intraocular pressure lowering effects of the renin inhibitor ABBOTT-64662 diacetate in animals. *J Ocul Pharmacol.* 1990;6(2):75–83.
- [150] Weinreb RN, Khaw PT. Primary open-angle glaucoma. *Lancet.* 2004;363(9422):1711–1720.
- [151] King A, Tuulonen A, Azuara-Blanco A. Glaucoma. *Brit Med J.* 2013;3467912:1–9.
- [152] Nuzzi R, Tridico F. Glaucoma: biological trabecular and neuroretinal pathology with perspectives of therapy innovation and preventive diagnosis. *Front Neurosci.* 2017;11:494.
- [153] Hirooka K, Baba T, Fujimura T, et al. Prevention of visual field defect progression with angiotensin-converting enzyme inhibitor in eyes with normal-tension glaucoma. *Am J Ophthalmol.* 2006;142(3):523–525.
- [154] Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. *Am J Ophthalmol.* 1998;126:487–497.
- [155] Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. *Am J Ophthalmol.* 1998;126:498–505.
- [156] Levin LA, Crowe ME, Quigley HA, et al. Neuroprotection for glaucoma: requirements for clinical translation. *Exp Eye Res.* 2017;157:34–37.
- [157] Tuulonen A, Forsman E, Hagman J, et al. Update on current care guideline: glaucoma. *Duodecim.* 2015;1314:356–358.
- [158] Johnson M. What controls aqueous humour outflow resistance? *Exp Eye Res.* 2006;82(4):545–557.
- [159] Acott TS, Kelley MJ, Keller KE, et al. Intraocular pressure homeostasis: maintaining balance in a high-pressure environment. *J Ocul Pharmacol Ther.* 2014;30(2-3):94–101.
- [160] To CH, Kong CW, Chan CY, et al. The mechanism of aqueous humour formation. *Clin Exp Optom.* 2002;85(6):335–349.
- [161] Freddo TF. The Glenn A. Fry Award Lecture 1992: aqueous humor proteins: a key for unlocking glaucoma? *Optom Vis Sci.* 1993;70:263–270.
- [162] McLaren JW, Ziai N, Brubaker RF. A simple three-compartment model of anterior segment kinetics. *Exp Eye Res.* 1993;56(3):355–366.
- [163] Barsotti MF, Bartels SP, Freddo TF, et al. The source of protein in the aqueous humor of the normal monkey eye. *Invest Ophthalmol Vis Sci.* 1992;33(3):581–595.
- [164] Freddo TF, Bartels SP, Barsotti MF, et al. The source of proteins in the aqueous humor of the normal rabbit. *Invest Ophthalmol Vis Sci.* 1990;31(1):125–137.
- [165] Janssen SF, Gorgels TG, van dS, et al. In silico analysis of the molecular machinery underlying aqueous humor production: potential implications for glaucoma. *J Clin Bioinformatics.* 2013;3(1):21.
- [166] Goel M, Picciani RG, Lee RK, et al. Aqueous humor dynamics: a review. *TOOPHTJ.* 2010;4(1):52–59.
- [167] Buys ES, Potter LR, Pasquale LR, et al. Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma. *Front Mol Neurosci.* 2014;7:38
- [168] Andrés-Guerrero V, García-Feijoo J, Konstas AG. Targeting schlemm's canal in the medical therapy of glaucoma: current and future considerations. *Adv Ther.* 2017;34(5):1049–1069.



- [169] Civan MM, Macknight AD. The ins and outs of aqueous humour secretion. *Exp Eye Res.* 2004;78(3):625–631.
- [170] Brubaker RF. The flow of aqueous humor in the human eye. *Trans Am Ophthalmol Soc.* 1982;80:391–474.
- [171] Mark HH. Aqueous humor dynamics in historical perspective. *Surv Ophthalmol.* 2010;55(1):89–100.
- [172] Huang AS, Francis BA, Weinreb RN. Structural and functional imaging of aqueous humour outflow: a review. *Clin Exp Ophthalmol.* 2018;46(2):158–168.
- [173] Baskaran M, Raman K, Ramani KK, et al. Intraocular pressure changes and ocular biometry during sirsasana (headstand posture) in yoga practitioners. *Ophthalmology.* 2006;113(8):1327–1332.
- [174] Dane S, Koçer I, Demirel H, et al. Long-term effects of mild exercise on intraocular pressure in athletes and sedentary subjects. *Int J Neurosci.* 2006;116(10):1207–1214.
- [175] Dane S, Koçer I, Demirel H, et al. Effect of acute submaximal exercise on intraocular pressure in athletes and sedentary subjects. *Int J Neurosci.* 2006;116(10):1223–1230.
- [176] Marcus DF, Krupin T, Podos SM, et al. The effect of exercise on intraocular pressure. I. human beings. *Invest Ophthalmol.* 1970;9(10):749–752.
- [177] Vieira GM, Oliveira HB, de Andrade DT, et al. Intraocular pressure variation during weight lifting. *Arch Ophthalmol.* 2006;124(9):1251–1254.
- [178] Dibas A, Yorito T. Glucocorticoid therapy and ocular hypertension. *Eur J Pharmacol.* 2016;787:57–71.
- [179] Caprioli J. The ciliary epithelia and aqueous humor. 9th ed. St. Louis: Mosby-Year book Inc; 1992.
- [180] Yamaguchi Y, Watanabe T, Hirakata A, et al. Localization and ontogeny of aquaporin-1 and -4 expression in iris and ciliary epithelial cells in rats. *Cell Tissue Res.* 2006;325(1):101–109.
- [181] Johnson M, McLaren JW, Overby DR. Unconventional aqueous humor outflow: a review. *Exp Eye Res.* 2017;158:94–111.
- [182] Weinreb RN. Uveoscleral outflow: the other outflow pathway. *J Glaucoma.* 2000;95:343–345.
- [183] Tamm ER. The trabecular meshwork outflow pathways: structural and functional aspects. *Exp Eye Res.* 2009;88(4):648–655.
- [184] Tan JC, Peters DM, Kaufman PL. Recent developments in understanding the pathophysiology of elevated intraocular pressure. *Curr Opin Ophthalmol.* 2006;17(2):168–174.
- [185] Tian B, Gabelt BT, Geiger B, et al. The role of the actomyosin system in regulating trabecular fluid outflow. *Exp Eye Res.* 2009;88(4):713–717.
- [186] Vranka JA, Acott TS. Pressure-induced expression changes in segmental flow regions of the human trabecular meshwork. *Exp Eye Res.* 2017;158:67–72.
- [187] Vranka JA, Kelley MJ, Acott TS, et al. Extracellular matrix in the trabecular meshwork: Intraocular pressure regulation and dysregulation in glaucoma. *Exp Eye Res.* 2015;133:112–125.
- [188] Tian B, Geiger B, Epstein DL, et al. Cytoskeletal involvement in the regulation of aqueous humor outflow. *Invest Ophthalmol Vis Sci.* 2000;41(3):619–623.
- [189] Fautsch MP, Johnson DH. Aqueous humor outflow: what do we know? Where will it lead us? *Invest Ophthalmol Vis Sci.* 2006;47(10):4181–4187.
- [190] Nilsson SF. The uveoscleral outflow routes. *Eye (Lond).* 1997;11(2):149–154.
- [191] Alm A, Nilsson SF. Uveoscleral outflow – a review. *Exp Eye Res.* 2009;88(4):760–768.
- [192] Lütjen-Drecoll E, Gabelt BT, Tian B, et al. Outflow of aqueous humor. *J Glaucoma.* 2001;105:42.
- [193] Yücel YH, Johnston MG, Ly T, et al. Identification of lymphatics in the ciliary body of the human eye: a novel “uveolymphatic” outflow pathway. *Exp Eye Res.* 2009;89(5):810–819.
- [194] Mehta A, Iyer L, Parmar S, et al. Oculohypotensive effect of perindopril in acute and chronic models of glaucoma in rabbits. *Can J Physiol Pharmacol.* 2010;88(5):595–600.
- [195] Constad WH, Fiore P, Samson C, et al. Use of an angiotensin converting enzyme inhibitor in ocular hypertension and primary open-angle glaucoma. *Am J Ophthalmol.* 1988;105(6):674–677.
- [196] Lotti VJ, Pawlowski N. Prostaglandins mediate the ocular hypotensive action of the angiotensin converting enzyme inhibitor MK-422 (enalaprilat) in African green monkeys. *J Ocul Pharmacol.* 1990;6(1):1–7.
- [197] Loftsson T, Thorisdóttir S, Fridriksdóttir H, et al. Enalaprilat and enalapril maleate eyedrops lower intraocular pressure in rabbits. *Acta Ophthalmol.* 2009;88(3):337–341.
- [198] Agarwal R, Agarwal P, Krasilnikova AV, et al. Mechanisms of angiotensin converting enzyme inhibitor-induced IOP reduction in normotensive rats. *Eur J Pharmacol.* 2014;730:8–13.
- [199] Agarwal R, Krasilnikova A, Mohamed SNL, et al. Topical losartan reduces IOP by altering TM morphology in rats with steroid-induced ocular hypertension. *Indian J Physiol Pharmacol.* 2018;622:238–248.
- [200] Abrams KL, Brooks DE, Laratta LJ, et al. Angiotensin converting enzyme system in the normal canine eye: pharmacological and physiological aspects. *J Ocul Pharmacol.* 1991;7(1):41–51.
- [201] Reitsamer HA, Kiel JW. Relationship between ciliary blood flow and aqueous production in rabbits. *Invest Ophthalmol Vis Sci.* 2003;44(9):3967–3971.
- [202] Inoue T, Yokoyama T, Koike H. The effect of angiotensin II on uveoscleral outflow in rabbits. *Curr Eye Res.* 2001;23(2):139–143.
- [203] Nilsson SF, Samuelsson M, Bill A, et al. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F<sub>2</sub> alpha-1-isopropylester in the cynomolgus monkey. *Exp Eye Res.* 1989;48(5):707–716.
- [204] Weinreb RN, Toris CB, Gabelt BT, et al. Effects of prostaglandins on the aqueous humor outflow pathways. *Surv Ophthalmol.* 2002;47(Suppl 1):53.
- [205] Momose N, Fukuo K, Morimoto S, et al. Captopril inhibits endothelin-1 secretion from endothelial cells through bradykinin. *Hypertension.* 1993;21(6\_pt\_2):921–924.

1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590



- [206] Haefliger IO, Flammer J, Lüscher TF. Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery. *Invest Ophthalmol Vis Sci.* 1992; 33(7):2340–2343.
- [207] Yao K, Tschudi M, Flammer J, et al. Endothelium-dependent regulation of vascular tone of the porcine ophthalmic artery. *Invest Ophthalmol Vis Sci.* 1991;32(6):1791–1798.
- [208] Garhöfer G, Schmetterer L. Nitric oxide: a drug target for glaucoma revisited. *Drug Discov Today.* 2019; 24(8):1614–1620.
- [209] Kotikoski H, Alajuuma P, Moilanen E, et al. Comparison of nitric oxide donors in lowering intraocular pressure in rabbits: role of cyclic GMP. *J Ocul Pharmacol Ther.* 2002;18(1):11–23.
- [210] Vaajanen A, Vapaatalo H, Kautiainen H, et al. Angiotensin (1-7) reduces intraocular pressure in the normotensive rabbit eye. *Invest Ophthalmol Vis Sci.* 2008;49(6):2557–2562.
- [211] Sharif NA. Novel potential treatment modalities for ocular hypertension: focus on angiotensin and bradykinin system axes. *J Ocul Pharmacol Ther.* 2015;31(3):131–145.
- [212] Foureaux G, Nogueira BS, Coutinho DC, et al. Activation of endogenous angiotensin converting enzyme 2 prevents early injuries induced by hyperglycemia in rat retina. *Braz J Med Biol Res.* 2015; 48(12):1109–1114.
- [213] Luhtala S, Vaajanen A, Oksala O, et al. Activities of angiotensin-converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues. *J Ocul Pharmacol Ther.* 2009;25(1):23–28.
- [214] Santos RA, Simoes eS, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. *PNAS.* 2003;100(14):8258–8263.
- [215] Foureaux G, Franca JR, Nogueira JC, et al. Ocular inserts for sustained release of the angiotensin-converting enzyme 2 activator, diminazene aceturate, to treat glaucoma in rats. *PLoS One.* 2015;10(7): e0133149.
- [216] Kaufman PL, Barany EH. Adrenergic drug effects on aqueous outflow facility following ciliary muscle retrodisplacement in the cynomolgus monkey. *Invest Ophthalmol Vis Sci.* 1981;20(5):644–651.
- [217] Quigley HA, Pitha IF, Welsbie DS, et al. Losartan treatment protects retinal ganglion cells and alters scleral remodeling in experimental glaucoma. *PLoS One.* 2015;10(10):e0141137.
- [218] Yang H, Hirooka K, Fukuda K, et al. Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma. *Invest Ophthalmol Vis Sci.* 2009;50(12):5800–5804.
- [219] Semba K, Namekata K, Guo X, et al. Renin-angiotensin system regulates neurodegeneration in a mouse model of normal tension glaucoma. *Cell Death Dis.* 2014;5(7):e1333–e1333.
- [220] Hazlewood RJ, Chen Q, Clark FK, et al. Differential effects of angiotensin II type I receptor blockers on reducing intraocular pressure and TGF $\beta$  signaling in the mouse retina. *PLoS One.* 2018;13(8):e0201719.
- [221] Takasago Y, Hirooka K, Nakano Y, et al. Elevated plasma aldosterone levels are associated with a reduction in retinal ganglion cell survival. *J Renin Angiotensin Aldosterone Syst.* 2018;19(3): 147032031879500.
- [222] Nitta E, Hirooka K, Tenkumo K, et al. Aldosterone: a mediator of retinal ganglion cell death and the potential role in the pathogenesis in normal-tension glaucoma. *Cell Death Dis.* 2013;4(7):e711–e711.
- [223] Kimura A, Namekata K, Guo X, et al. Targeting oxidative stress for treatment of glaucoma and optic neuritis. *Oxid Med Cell Longev.* 2017;2017:1–8.
- [224] Agarwal P, Agarwal R. Trabecular meshwork ECM remodeling in glaucoma: could RAS be a target. *Expert Opin Ther Targets.* 2018;22(7):629–638. ?
- [225] Shen F, Zhang L, Liu T. Effects of angiotensin II on the 3H-TdR incorporation and synthesis of collagen in cultured bovine trabecular meshwork cells. *Yan Ke Xue Bao.* 2001;17(4):209–212.
- [226] May CA. Could mineralocorticoids play a role in the pathophysiology of open angle glaucoma. ? *J Ophthalmol.* 2012;2012:1–5.
- [227] Mirshahi A, Mirshahi M, Nicolas C, et al. The mineralocorticoid hormone receptor and action in the eye. *Biochem Biophys Res Comm.* 1996;219(1): 150–156.
- [228] Gugleta K, Orgül S, Stümpfig D, et al. Fludrocortisone in the treatment of systemic hypotension in primary open-angle glaucoma patients. *Int Ophthalmol.* 1999;23(1):25–30.
- [229] Höhn R, Mirshahi A, Nickels S, et al. Cardiovascular medication and intraocular pressure: results from the Gutenberg Health Study. *Br J Ophthalmol.* 2017; 101(12):1633–1637.
- [230] Langman MJ, Lancashire RJ, Cheng KK, et al. Systemic hypertension and glaucoma: mechanisms in common and co-occurrence. *Br J Ophthalmol.* 2005;89(8):960–963.
- [231] Grunwald JE, Riva CE, Stone RA, et al. Retinal autoregulation in open-angle glaucoma. *Ophthalmology.* 1984;91(12):1690–1694.
- [232] Piltz-Seymour J, Grunwald JE, Hariprasad SM, et al. Optic nerve blood flow is diminished in eyes of primary open-angle glaucoma suspects. *Am J Ophthalmol.* 2001;132(1):63–69.
- [233] De Moraes CG, Cioffi GA, Weinreb RN, et al. Perspective: new recommendations for the treatment of systemic hypertension and their potential implications for glaucoma management. *J Glaucoma.* 2018;27:1–571.
- [234] Ho H, Shi Y, Chua J, et al. Association of systemic medication use with intraocular pressure in a multi-ethnic Asian population: the Singapore epidemiology of eye diseases study. *JAMA Ophthalmol.* 2017;135(3):196–202.
- [235] Khawaja AP, Chan MPY, Broadway DC, et al. Systemic medication and intraocular pressure in a British population: the EPIC-Norfolk Eye Study. *Ophthalmology.* 2014;121(8):1501–1507.